{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:37:22Z","timestamp":1794605842479,"version":"4.9.1"},"reference-count":297,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T00:00:00Z","timestamp":1640476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is characterized by the excessive and detrimental accumulation of liver fat as a result of high-caloric intake and\/or cellular and molecular abnormalities. The prevalence of this pathological event is increasing worldwide, and is intimately associated with obesity and type 2 diabetes mellitus, among other comorbidities. To date, only therapeutic strategies based on lifestyle changes have exhibited a beneficial impact on patients with NAFLD, but unfortunately this approach is often difficult to implement, and shows poor long-term adherence. For this reason, great efforts are being made to elucidate and integrate the underlying pathological molecular mechanism, and to identify novel and promising druggable targets for therapy. In this regard, a large number of clinical trials testing different potential compounds have been performed, albeit with no conclusive results yet. Importantly, many other clinical trials are currently underway with results expected in the near future. Here, we summarize the key aspects of NAFLD pathogenesis and therapeutic targets in this frequent disorder, highlighting the most recent advances in the field and future research directions.<\/jats:p>","DOI":"10.3390\/biomedicines10010046","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T01:00:54Z","timestamp":1640566854000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets"],"prefix":"10.3390","volume":"10","author":[{"given":"Alvaro","family":"Santos-Laso","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Guti\u00e9rrez-Larra\u00f1aga","sequence":"additional","affiliation":[{"name":"Department of Immunology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-2202","authenticated-orcid":false,"given":"Marta","family":"Alonso-Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Medina","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Iruzubieta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"},{"name":"National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-3833","authenticated-orcid":false,"given":"Mar\u00eda Teresa","family":"Arias-Loste","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"},{"name":"National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-427X","authenticated-orcid":false,"given":"Marcos","family":"L\u00f3pez-Hoyos","sequence":"additional","affiliation":[{"name":"Department of Immunology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8248-0172","authenticated-orcid":false,"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Marqu\u00e9s de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain"},{"name":"National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1038\/s41598-018-29735-6","article-title":"Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin","volume":"8","author":"Ogawa","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/hep4.1134","article-title":"Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies","volume":"2","author":"Nasr","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep4.1419","article-title":"Mortality related to nonalcoholic fatty liver disease is increasing in the United States","volume":"3","author":"Paik","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rosato, V., Masarone, M., Dallio, M., Federico, A., Aglitti, A., and Persico, M. (2019). NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16183415"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Juanola, O., Mart\u00ednez-L\u00f3pez, S., Franc\u00e9s, R., and G\u00f3mez-Hurtado, I. (2021). Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18105227"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A.D., Loguercio, C., Serviddio, G., and Federico, A. (2021). Immunity as cornerstone of non-alcoholic fatty liver disease: The contribution of oxidative stress in the disease progression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010436"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10715762.2015.1078461","article-title":"Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease","volume":"49","author":"Ashraf","year":"2015","journal-title":"Free Radic. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103264","DOI":"10.1016\/j.ebiom.2021.103264","article-title":"Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study","volume":"65","author":"Fryk","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105972","DOI":"10.1016\/j.biocel.2021.105972","article-title":"Unwrapping the mechanisms of ceramide and fatty acid-initiated signals leading to immune-inflammatory responses in obesity","volume":"135","author":"Kucuk","year":"2021","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.3748\/wjg.v16.i37.4652","article-title":"Roles of liver innate immune cells in nonalcoholic fatty liver disease","volume":"16","author":"Zhan","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1590\/s0004-2803.202000000-47","article-title":"Distinct phenotype of non-alcoholic fatty liver disease in patients with low levels of free copper and of ceruloplasmin","volume":"57","author":"Nunes","year":"2020","journal-title":"Arq. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cmet.2012.04.001","article-title":"Inflammation and lipid signaling in the etiology of insulin resistance","volume":"15","author":"Glass","year":"2012","journal-title":"Cell Metab."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity (2016). EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fphar.2018.01566","article-title":"Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes Mellitus: Insulin resistance between hepatic and peripheral tissues","volume":"9","author":"Mu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1172\/JCI96702","article-title":"Fructose metabolism and metabolic disease","volume":"128","author":"Hannou","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_22","first-page":"69","article-title":"The NF-kappaB-mediated control of ROS and JNK signaling","volume":"21","author":"Bubici","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune responses in the liver","volume":"36","author":"Kubes","year":"2018","journal-title":"Ann. Rev. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41579-020-0438-4","article-title":"Gut microbial metabolites as multi-kingdom intermediates","volume":"19","author":"Krautkramer","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"154320","DOI":"10.1016\/j.metabol.2020.154320","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","volume":"111","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bbadis.2018.06.023","article-title":"Animal models of NAFLD from a hepatologist\u2019s point of view","volume":"1865","author":"Jahn","year":"2019","journal-title":"Biochim. Biophys. Acta\u2014Mol. Basis Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: A distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.metabol.2018.11.009","article-title":"Metabolically healthy versus metabolically unhealthy obesity","volume":"92","author":"Iacobini","year":"2019","journal-title":"Metabolism"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1097\/MD.0000000000002159","article-title":"Visceral obesity predicts significant fibrosis in patients with non-alcoholic fatty liver disease","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40519-015-0215-y","article-title":"Association of body composition and eating behavior in the normal weight obese syndrome","volume":"21","author":"Tyndall","year":"2016","journal-title":"Eat. Weight Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","article-title":"Metabolomic identification of subtypes of nonalcoholic steatohepatitis","volume":"152","author":"Alonso","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_34","first-page":"269","article-title":"Interim analysis from a 72 week, double-blind, placebo-controlled, multicenter, paired liver biopsy study of endoscopic sleeve gastroplasty in patients with non-alcoholic steatohepatitis (NASH)","volume":"75","author":"Ampuero","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"k2340","DOI":"10.1136\/bmj.k2340","article-title":"Dietary carbohydrates: Role of quality and quantity in chronic disease","volume":"361","author":"Ludwig","year":"2018","journal-title":"BMJ"},{"key":"ref_36","unstructured":"GBD Diet Collaborators (2019). Health effects of dietary risks in 195 countries, 1990\u20132017: A systematic analysis for the global burden of disease study 2017. Lancet, 393, 1958\u20131972."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mei, S., Yang, X., Guo, H., Gu, H., Zha, L., Cai, J., Li, X., Liu, Z., Bennett, B.J., and He, L. (2014). A small amount of dietary carbohydrate can promote the HFD-induced insulin resistance to a maximal level. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100875"},{"key":"ref_38","first-page":"64","article-title":"Comorbidities and non-alcoholic fatty liver disease: The chicken, the egg, or both?","volume":"36","author":"Glass","year":"2019","journal-title":"Fed. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.endinu.2017.12.011","article-title":"Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes","volume":"65","author":"Cuadrado","year":"2018","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_43","unstructured":"Ortiz, P. (2021). Serum metabolomics-based steatohepatitis score for the noninvasive identification of patients with non-alcoholic steatohepatitis (NASH) in multiethnic, including type 2 diabetes mellitus population. J. Hepatol., 75, Available online: https:\/\/www.postersessiononline.eu\/173580348_eu\/congresos\/ILC2021\/aula\/-PO_1518_ILC2021.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, Y., Wang, J., Tang, Y., Han, X., Liu, B., Hu, H., Li, X., Yang, K., Yuan, J., and Miao, X. (2017). Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174291"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2931985","article-title":"The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes","volume":"2016","author":"Forlani","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_46","first-page":"e139946","article-title":"Short-term overnutrition induces white adipose tissue insulin resistance through sn-1,2-diacylglycerol\u2014PKC\u03b5\u2014insulin receptorT1160 phosphorylation","volume":"6","author":"Lyu","year":"2021","journal-title":"JCI Insight"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cmet.2020.08.001","article-title":"A membrane-bound diacylglycerol species induces PKC\u03f5-mediated hepatic insulin resistance","volume":"32","author":"Lyu","year":"2020","journal-title":"Cell Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R468","DOI":"10.1152\/ajpregu.00521.2016","article-title":"Mice lacking PKC-\u03b8 in skeletal muscle have reduced intramyocellular lipid accumulation and increased insulin responsiveness in skeletal muscle","volume":"314","author":"Peck","year":"2018","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.tem.2016.06.005","article-title":"The sweet path to metabolic demise: Fructose and lipid synthesis","volume":"27","author":"Herman","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-020-01286-8","article-title":"Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: A review","volume":"19","author":"Kolczynska","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref_51","first-page":"447","article-title":"Resolving the paradox of hepatic insulin resistance","volume":"7","author":"Santoleri","year":"2019","journal-title":"CMGH"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2011.07.019","article-title":"Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver","volume":"56","author":"Dentin","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Song, Z., Yang, H., Zhou, L., and Yang, F. (2019). Glucose-sensing transcription factor MondoA\/ChREBP as targets for type 2 diabetes: Opportunities and challenges. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205132"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12977","DOI":"10.1038\/ncomms12977","article-title":"Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity","volume":"7","author":"Kubota","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Sakurai, Y., Kubota, N., Yamauchi, T., and Kadowaki, T. (2021). Role of insulin resistance in MAFLD. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084156"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/db16-1167","article-title":"Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: Results from the san antonio metabolism study","volume":"66","author":"Gastaldelli","year":"2017","journal-title":"Diabetes"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10989","DOI":"10.1074\/jbc.M113.527002","article-title":"Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis","volume":"289","author":"DeBosch","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI81993","article-title":"ChREBP regulates fructose-induced glucose production independently of insulin signaling","volume":"126","author":"Kim","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., and Persico, M. (2021). The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights. Nutrients, 13.","DOI":"10.3390\/nu13041314"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.celrep.2016.09.069","article-title":"ATP-citrate Lyase controls a glucose-to-acetate metabolic switch","volume":"17","author":"Zhao","year":"2016","journal-title":"Cell Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/en.2016-1577","article-title":"Posttranslational modifications of lipid-activated nuclear receptors: Focus on metabolism","volume":"158","author":"Becares","year":"2016","journal-title":"Endocrinology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Shin, H., Lee, Y., Shin, M., Cho, S., Zouboulis, C., Kim, M., Lee, D., and Chung, J. (2021). Histone deacetylase 1 reduces lipogenesis by suppressing SREBP1 transcription in human sebocyte cell line SZ95. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094477"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chyau, C.-C., Wang, H.-F., Zhang, W.-J., Chen, C.-C., Huang, S.-H., Chang, C.-C., and Peng, R.Y. (2020). Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL\/6 Mice Model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 pathway. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010360"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"597648","DOI":"10.3389\/fendo.2020.597648","article-title":"Chronic inflammation in non-alcoholic steatohepatitis: Molecular mechanisms and therapeutic strategies","volume":"11","author":"Luci","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4049\/jimmunol.1501668","article-title":"Hepatocytes as immunological agents","volume":"196","author":"Crispe","year":"2016","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.tem.2018.08.003","article-title":"Role of innate immune signaling in non-alcoholic fatty liver disease","volume":"29","author":"Cai","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_68","first-page":"1","article-title":"The crosstalk between hypoxia and innate immunity in the development of obesity-related nonalcoholic fatty liver disease","volume":"2015","author":"Crespo","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"106368","DOI":"10.1016\/j.intimp.2020.106368","article-title":"Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-\u03baB pathways","volume":"82","author":"Wu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"173461","DOI":"10.1016\/j.ejphar.2020.173461","article-title":"Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS\/TLR4 and autophagy pathways","volume":"887","author":"Ahmed","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI83885","article-title":"Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9","volume":"126","author":"Santoro","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1042\/CS20160838","article-title":"TLR9 is up-regulated in human and murine NASH: Pivotal role in inflammatory recruitment and cell survival","volume":"131","author":"Mridha","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/hepr.12883","article-title":"Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease","volume":"47","author":"Mitsuyoshi","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2012.09.008","article-title":"Sterile inflammation in the liver","volume":"143","author":"Kubes","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: Sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/path.2888","article-title":"Increased production of sonic hedgehog by ballooned hepatocytes","volume":"224","author":"Rangwala","year":"2011","journal-title":"J. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1194\/jlr.M063412","article-title":"Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1\u03b1-dependent manner","volume":"57","author":"Kakazu","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"627424","DOI":"10.3389\/fimmu.2020.627424","article-title":"Extracellular vesicles as inflammatory drivers in NAFLD","volume":"11","author":"Srinivas","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Povero, D., Eguchi, A., Li, H., Johnson, C.D., Papouchado, B.G., Wree, A., Messer, K., and Feldstein, A.E. (2014). Circulating extracellular vesicles with specific proteome and liver MicroRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0113651"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2012.04.031","article-title":"Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with Hepatitis C or nonalcoholic steatohepatitis","volume":"143","author":"Kornek","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.2741\/1765","article-title":"Apoptosis in alcoholic and nonalcoholic steatohepatitis","volume":"10","author":"Ariel","year":"2005","journal-title":"Front. Biosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1053\/jhep.2003.50472","article-title":"Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression","volume":"38","author":"Canbay","year":"2003","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1678-y","article-title":"Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis","volume":"10","author":"Tsurusaki","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","article-title":"Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis","volume":"74","author":"Gaul","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jhep.2020.04.001","article-title":"Lytic cell death in metabolic liver disease","volume":"73","author":"Gautheron","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"Reilly","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and Type 2 diabetes","volume":"10","author":"Zatterale","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease","volume":"149","author":"Korf","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/gutjnl-2016-313654","article-title":"Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice","volume":"67","author":"Bijnen","year":"2017","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer","volume":"15","author":"Divella","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00125-015-3769-3","article-title":"Circulating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"59","author":"Polyzos","year":"2016","journal-title":"Diabetologia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/jgh.15029","article-title":"Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels","volume":"35","author":"Salman","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Iruzubieta, P., Medina, J.M., Fern\u00e1ndez-L\u00f3pez, R., Crespo, J., and De La Cruz, F. (2020). A role for gut microbiome fermentative pathways in fatty liver disease progression. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051369"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut\u2013liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"660179","DOI":"10.3389\/fimmu.2021.660179","article-title":"The role of the gut-liver axis in metabolic dysfunction-associated fatty liver disease","volume":"12","author":"Albillos","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/hep4.1284","article-title":"Gut microbial metabolism and nonalcoholic fatty liver disease","volume":"3","author":"Sharpton","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hep.27489","article-title":"Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cgh.2018.08.065","article-title":"Emerging role of the gut microbiome in nonalcoholic fatty liver disease: From composition to function","volume":"17","author":"Sharpton","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0168-8278(18)30275-7","article-title":"Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD","volume":"68","author":"Caussy","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01973-8","article-title":"Meta-analysis of gut microbiome studies identifies disease-specific and shared responses","volume":"8","author":"Duvallet","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/cmi.2015.97","article-title":"Hepatocytes: A key cell type for innate immunity","volume":"13","author":"Zhou","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Norris, C.A., He, M., Kang, L.-I., Ding, M., Radder, J., Haynes, M.M., Yang, Y., Paranjpe, S., Bowen, W.C., and Orr, A. (2014). Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096053"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Jia, Q., Li, C., Xia, Y., Zhang, Q., Wu, H., Du, H., Liu, L., Wang, C., Shi, H., and Guo, X. (2015). Association between complement C3 and prevalence of fatty liver disease in an adult population: A cross-sectional study from the Tianjin chronic low-grade systemic inflammation and health (TCLSIHealth) cohort study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122026"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.23228","article-title":"Activation of the complement system in human nonalcoholic fatty liver disease","volume":"50","author":"Rensen","year":"2009","journal-title":"Hepatology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fphys.2020.00873","article-title":"Prominent receptors of liver sinusoidal endothelial cells in liver homeostasis and disease","volume":"11","author":"Pandey","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e143690","DOI":"10.1172\/JCI143690","article-title":"Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis","volume":"131","author":"Furuta","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI73722","article-title":"Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis","volume":"125","author":"Weston","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Furuta, K., Guo, Q., Hirsova, P., and Ibrahim, S.H. (2020). Emerging roles of liver sinusoidal endothelial cells in nonalcoholic steatohepatitis. Biology, 9.","DOI":"10.3390\/biology9110395"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.26937","article-title":"The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease","volume":"59","author":"Gadd","year":"2014","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cellimm.2018.08.006","article-title":"Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release","volume":"332","author":"Pan","year":"2018","journal-title":"Cell. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1172\/JCI121842","article-title":"STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis","volume":"129","author":"Yu","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep.26081","article-title":"Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice","volume":"57","author":"Miura","year":"2013","journal-title":"Hepatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.26607","article-title":"M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease","volume":"59","author":"Wan","year":"2014","journal-title":"Hepatology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1002\/jcp.30218","article-title":"Ghrelin ameliorates nonalcoholic steatohepatitis induced by chronic low-grade inflammation via blockade of Kupffer cell M1 polarization","volume":"236","author":"Yin","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/jgh.15025","article-title":"Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4\/NF-\u03baB signaling pathway","volume":"35","author":"Wu","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2020.01169","article-title":"Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis","volume":"11","author":"Li","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Reid, D.T., Reyes, J.L., McDonald, B.A., Vo, T., Reimer, R.A., and Eksteen, B. (2016). Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159524"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02325-2","article-title":"Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4\u2013MD2 complex","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep4.1237","article-title":"Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"2","author":"Glass","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/4570219","article-title":"Circulating neutrophils of nonalcoholic steatohepatitis patients show an activated phenotype and suppress T lymphocytes activity","volume":"2020","author":"Antonucci","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/MEG.0000000000001393","article-title":"Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease","volume":"31","author":"Khoury","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/hep.31031","article-title":"Interleukin-22 Ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets","volume":"72","author":"Hwang","year":"2019","journal-title":"Hepatology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12020-017-1323-4","article-title":"Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice","volume":"57","author":"Ou","year":"2017","journal-title":"Endocrine"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2353\/ajpath.2009.080999","article-title":"Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis","volume":"175","author":"Rensen","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Rensen, S.S., Bieghs, V., Xanthoulea, S., Arfianti, E., Bakker, J.A., Shiri-Sverdlov, R., Hofker, M.H., Greve, J.W., and Buurman, W.A. (2012). Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0052411"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/ars.2014.6108","article-title":"Myeloperoxidase\u2013hepatocyte\u2013stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis","volume":"23","author":"Pulli","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10020-019-0084-3","article-title":"Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes","volume":"25","author":"Mirea","year":"2019","journal-title":"Mol. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbrc.2019.08.111","article-title":"Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism","volume":"518","author":"Chen","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jhep.2016.05.041","article-title":"Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2","volume":"65","author":"Ye","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"Sud","year":"2018","journal-title":"Hepatology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2014.07.006","article-title":"CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis","volume":"61","author":"Zhang","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Stiglund, N., Strand, K., Cornillet, M., St\u00e5l, P., Thorell, A., Zimmer, C.L., N\u00e4slund, E., Karlgren, S., Nilsson, H., and Mellgren, G. (2019). Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01255"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hep.23253","article-title":"Major histocompatibility complex class I-related chains A and B (MIC A\/B): A novel role in nonalcoholic steatohepatitis","volume":"51","author":"Kahraman","year":"2010","journal-title":"Hepatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3389\/fimmu.2019.02180","article-title":"The obese liver environment mediates conversion of NK cells to a less cytotoxic ILC1-Like phenotype","volume":"10","author":"Cuff","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.25694","article-title":"Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase","volume":"56","author":"Luka","year":"2012","journal-title":"Hepatology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.28389","article-title":"NKp46+ natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice","volume":"63","author":"Krueger","year":"2016","journal-title":"Hepatology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/liv.14307","article-title":"Hepatic NK cells attenuate fibrosis progression of non-alcoholic steatohepatitis in dependent of CXCL10-mediated recruitment","volume":"40","author":"Fan","year":"2019","journal-title":"Liver Int."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/eji.201747294","article-title":"ILC-poiesis: Ensuring tissue ILC differentiation at the right place and time","volume":"49","author":"Lim","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"607011","DOI":"10.3389\/fendo.2020.607011","article-title":"Oxidation-specific epitopes in non-alcoholic fatty liver disease","volume":"11","author":"Hendrikx","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.freeradbiomed.2018.06.015","article-title":"B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD)","volume":"124","author":"Sutti","year":"2018","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/1751-2980.12362","article-title":"Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-inflammatory cytokines and regulating intrahepatic T cells","volume":"17","author":"Zhang","year":"2016","journal-title":"J. Dig. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/hep.31755","article-title":"Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling","volume":"74","author":"Barrow","year":"2021","journal-title":"Hepatology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2020.05.047","article-title":"Blocking integrin \u03b14\u03b27-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis","volume":"73","author":"Rai","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_154","first-page":"253","article-title":"NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s42255-019-0076-1","article-title":"Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution","volume":"1","author":"Haas","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10875-011-9635-2","article-title":"The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis","volume":"32","author":"Solari","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_157","first-page":"G891","article-title":"IFN-\u03b3 deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet","volume":"305","author":"Luo","year":"2013","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Diedrich, T., Kummer, S., Galante, A., Drolz, A., Schlicker, V., Lohse, A.W., Kluwe, J., Eberhard, J.M., and Wiesch, J.S.Z. (2020). Characterization of the immune cell landscape of patients with NAFLD. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230307"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory t cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2015","journal-title":"J. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/hep.26746","article-title":"IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice","volume":"59","author":"Harley","year":"2014","journal-title":"Hepatology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.intimp.2014.09.024","article-title":"3, 3\u2032-diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg\/Th17 cells to Treg dominance","volume":"23","author":"Liu","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20150405","article-title":"The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice","volume":"130","author":"Rolla","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0463.2011.02746.x","article-title":"Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis","volume":"119","author":"Marmur","year":"2011","journal-title":"APMIS"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"He, B., Wu, L., Xie, W., Shao, Y., Jiang, J., Zhao, Z., Yan, M., Chen, Z., and Cui, D. (2017). The imbalance of Th17\/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol., 18.","DOI":"10.1186\/s12865-017-0215-y"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"7616","DOI":"10.1126\/sciimmunol.aai7616","article-title":"Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome","volume":"2","author":"Ghazarian","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.1964","article-title":"CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity","volume":"15","author":"Nishimura","year":"2009","journal-title":"Nat. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1096\/fj.201802534RR","article-title":"The immunoregulatory effects of CD8 T-cell\u2013derived perforin on diet-induced nonalcoholic steatohepatitis","volume":"33","author":"Wang","year":"2019","journal-title":"FASEB J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s10875-011-9571-1","article-title":"Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis","volume":"31","author":"Inzaugarat","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3748\/wjg.v17.i13.1725","article-title":"Intrahepatic natural killer T cell populations are increased in human hepatic steatosis","volume":"17","author":"Adler","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.4049\/jimmunol.1800614","article-title":"Differential activation of hepatic invariant NKT cell subsets plays a key role in progression of nonalcoholic steatohepatitis","volume":"201","author":"Maricic","year":"2018","journal-title":"J. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/MEG.0b013e32831bc3d6","article-title":"Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease","volume":"21","author":"Tajiri","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/hep.23599","article-title":"Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease","volume":"51","author":"Syn","year":"2010","journal-title":"Hepatology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/hep4.1041","article-title":"Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis","volume":"1","author":"Bhattacharjee","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00535-010-0272-y","article-title":"Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet","volume":"45","author":"Miyagi","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/hep.20826","article-title":"Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease","volume":"42","author":"Li","year":"2005","journal-title":"Hepatology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.23292","article-title":"Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis","volume":"51","author":"Kremer","year":"2010","journal-title":"Hepatology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"060","DOI":"10.1055\/s-0037-1621709","article-title":"Mucosal-associated invariant T cells in chronic inflammatory liver disease","volume":"38","author":"Bolte","year":"2018","journal-title":"Semin. Liver Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.molmet.2019.06.025","article-title":"MAIT cells in metabolic diseases","volume":"27","author":"Bertrand","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04450-y","article-title":"Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver","volume":"9","author":"Hegde","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3389\/fimmu.2018.01994","article-title":"Mucosal-associated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization","volume":"9","author":"Li","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1038\/ncomms13839","article-title":"The microbiota maintain homeostasis of liver-resident \u03b3\u03b4T-17 cells in a lipid antigen\/CD1d-dependent manner","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_184","first-page":"477","article-title":"\u03b3\u03b4 T cells promote steatohepatitis by orchestrating innate and adaptive immune programming","volume":"71","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: A patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_188","first-page":"1","article-title":"Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): Study protocol for a randomized controlled trial (TESLA-NASH study)","volume":"22","author":"Rivas","year":"2021","journal-title":"Trials"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cgh.2016.12.012","article-title":"Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients","volume":"15","author":"Sharaiha","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"76984","DOI":"10.18632\/oncotarget.12764","article-title":"Phosphorylation of PPAR\u03b3 at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4","volume":"7","author":"Shu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: The good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1036","article-title":"Treating fatty liver disease by modulating mitochondrial pyruvate metabolism","volume":"1","author":"Colca","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"LIDO study group long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2009","journal-title":"Hepatology"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term Pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_199","first-page":"24","article-title":"Pioglitazone use and risk of bladder cancer: A systematic literature review and meta-analysis of observational studies","volume":"10","author":"Khanfir","year":"2018","journal-title":"Diabetol. Int."},{"key":"ref_200","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: Safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_202","first-page":"1","article-title":"MD001, a novel Peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist, improves glucose and lipid metabolism","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast growth factors in control of lipid metabolism","volume":"30","author":"Struik","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"ref_207","first-page":"9","article-title":"Efficacy and safety of pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis: Results from the phase 2b, randomized, double-blind, placebo-controlled FALCON 1 study","volume":"74","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_208","first-page":"65","article-title":"Comparison of manual vs machine learning approaches to liver biopsy scoring for NASH and fibrosis: A post hoc analysis of the FALCON 1 study","volume":"74","author":"Shevell","year":"2021","journal-title":"Hepatology"},{"key":"ref_209","first-page":"67","article-title":"Effect of pegbelfermin on noninvasive biomarkers of NASH and fibrosis: A post hoc analysis of the FALCON 1 trial","volume":"74","author":"Sanyal","year":"2021","journal-title":"Hepatology"},{"key":"ref_210","first-page":"27","article-title":"Efficacy and safety of pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis: Results from the phase 2b, randomized, double-blind, placebo-controlled FALCON 2 study","volume":"74","author":"Abdelmalek","year":"2021","journal-title":"Hepatology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/db19-140-LB","article-title":"140-LB: NGM313, a novel activator of b-Klotho\/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects","volume":"68","author":"Depaoli","year":"2019","journal-title":"Diabetes"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA Carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.30674","article-title":"MRI assessment of treatment response in HIV-associated NAFLD: A randomized trial of a stearoyl-coenzyme-a-desaturase-1 inhibitor (ARRIVE Trial)","volume":"70","author":"Ajmera","year":"2019","journal-title":"Hepatology"},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Kucsera, D., T\u00f3th, V.E., Gerg\u0151, D., V\u00f6r\u00f6s, I., On\u00f3di, Z., G\u00f6rbe, A., Ferdinandy, P., and Varga, Z.V. (2021). Characterization of the CDAA diet-induced non-alcoholic steatohepatitis model: Sex-specific differences in inflammation, fibrosis, and cholesterol metabolism in middle-aged mice. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.609465"},{"key":"ref_219","first-page":"275","article-title":"Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD","volume":"15","author":"Gawrieh","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"e13519","DOI":"10.1111\/eci.13519","article-title":"Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches","volume":"51","author":"Dongiovanni","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.phrs.2018.09.025","article-title":"Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"137","author":"Bifari","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Masmiquel","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): A randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_243","first-page":"131","article-title":"Semaglutide treatment in subjects with NAFLD: Effects assessed by magnetic resonance elastography and magnetic resonance imaging proton density fat fraction","volume":"72","author":"Flint","year":"2020","journal-title":"Hepatology"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S0168-8278(20)30655-3","article-title":"Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: A 54-week analysis of a randomized phase 2b study","volume":"73","author":"Nahra","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212264","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitors: A growing class of antidiabetic agents","volume":"3","author":"Vivian","year":"2014","journal-title":"Drugs Context"},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Perakakis, N., Chrysafi, P., Feigh, M., Veidal, S., and Mantzoros, C. (2021). Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126332"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/2211-5463.12598","article-title":"Inhibition of sodium glucose cotransporter 2 (SGLT 2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)","volume":"9","author":"Goto","year":"2019","journal-title":"FEBS Open Bio"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Honda, Y., Imajo, K., Kato, T., Kessoku, T., Ogawa, Y., Tomeno, W., Kato, S., Mawatari, H., Fujita, K., and Yoneda, M. (2016). The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146337"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: Results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.diabet.2018.08.001","article-title":"SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes","volume":"44","author":"Bajaj","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: A prospective, open-label, uncontrolled study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr. Ther. Res."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00535-017-1364-8","article-title":"Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: Pooled and subgroup analyses of clinical trials","volume":"53","author":"Seko","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40261-016-0383-1","article-title":"Effectiveness of Ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors","volume":"36","author":"Ohki","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s13340-016-0302-y","article-title":"The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus","volume":"8","author":"Bando","year":"2017","journal-title":"Diabetol. Int."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/14656566.2017.1363888","article-title":"Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes","volume":"18","author":"Ohta","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic Steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/bcp.14248","article-title":"Effects of the dual sodium\u2013glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure","volume":"86","author":"Kozlovski","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30425-2","article-title":"JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study","volume":"68","author":"Diehl","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: Evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"150","DOI":"10.15171\/mejdd.2017.66","article-title":"Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: A randomized clinical trial","volume":"9","author":"Behrouz","year":"2017","journal-title":"Middle East J. Dig. Dis."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/1735-1995.193178","article-title":"Do symbiotic and vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial","volume":"21","author":"Shidfar","year":"2016","journal-title":"J. Res. Med. Sci."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jn\/nxy088","article-title":"Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial","volume":"148","author":"Bakhshimoghaddam","year":"2018","journal-title":"J. Nutr."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3350\/cmh.2018.0006","article-title":"Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease","volume":"24","author":"Sayari","year":"2018","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, c-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: A clinical trial","volume":"7","author":"Askari","year":"2016","journal-title":"Int. J. Prev. Med."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"e46017","DOI":"10.5812\/ircmj.46017","article-title":"The effect of probiotic and\/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: A double blind randomized clinical trial","volume":"19","author":"Javadi","year":"2017","journal-title":"Iran. Red Crescent Med. J."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-016-0300-5","article-title":"Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: A systematic review of randomized controlled trials","volume":"8","author":"Kristensen","year":"2016","journal-title":"Genome Med."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cmet.2017.09.008","article-title":"Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition","volume":"26","author":"Kootte","year":"2017","journal-title":"Cell Metab."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aad8852","article-title":"Durable coexistence of donor and recipient strains after fecal microbiota transplantation","volume":"352","author":"Li","year":"2016","journal-title":"Science"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/gutjnl-2019-318320","article-title":"Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time","volume":"69","author":"Scheithauer","year":"2020","journal-title":"Gut"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cgh.2019.07.006","article-title":"Effects of fecal microbiota transplantation with oral capsules in obese patients","volume":"18","author":"Allegretti","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"e21871","DOI":"10.1096\/fj.202100939R","article-title":"Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases","volume":"35","author":"Liu","year":"2021","journal-title":"FASEB J."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/hep.31623","article-title":"Phage therapy for alcohol-associated hepatitis","volume":"73","author":"Suh","year":"2020","journal-title":"Hepatology"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cmet.2019.11.006","article-title":"Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"e13947","DOI":"10.1111\/ijcp.13947","article-title":"Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy","volume":"75","author":"Mikolasevic","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"18.1","DOI":"10.1146\/annurev-physiol-021115-105331","article-title":"Pathophysiology and mechanisms of nonalcoholic fatty liver disease","volume":"78","author":"Haas","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: Facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/lt.25003","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation","volume":"24","author":"Younossi","year":"2017","journal-title":"Liver Transplant."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH Trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: Systematic review and meta-analysis","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_294","first-page":"517","article-title":"Non-alcoholic fatty liver disease and psoriasis\u2014Is there a shared proinflammatory network?","volume":"19","author":"Heitmann","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/MEG.0000000000001679","article-title":"Non-alcoholic fatty liver disease in inflammatory bowel disease patients","volume":"32","author":"Karaivazoglou","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: Comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.jhepr.2020.100148","article-title":"Stratification of patients in NASH clinical trials: A pitfall for trial success","volume":"2","author":"Ampuero","year":"2020","journal-title":"JHEP Rep."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:53:47Z","timestamp":1760169227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,26]]},"references-count":297,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["biomedicines10010046"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10010046","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,26]]}}}